scholarly journals Larotrectinib (Vitrakvi)

2021 ◽  
Vol 1 (11) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Gene Fusion ◽  
Pediatric Patients ◽  
Drug Class ◽  
Treatment Options ◽  
Acquired Resistance ◽  
Resistance Mutation ◽  
Clinical Effectiveness ◽  
Oral Solution ◽  
Severe Morbidity ◽  
Clinician Perspectives

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses larotrectinib (Vitrakvi); 25 mg and 100 mg capsules (as larotrectinib sulphate) and 20 mg/mL oral solution (as larotrectinib sulphate). Indication: For the treatment of adult and pediatric patients with solid tumours that: have an NTRK gene fusion without a known acquired resistance mutation are metastatic or where surgical resection is likely to result in severe morbidity have no satisfactory treatment options

scholarly journals Larotrectinib (Vitrakvi)

2021 ◽  
Vol 1 (9) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Gene Fusion ◽  
Treatment Options ◽  
Single Agent ◽  
Locally Advanced ◽  
Acquired Resistance ◽  
Resistance Mutation ◽  
Solid Tumours ◽  
The Cost ◽  
Tyrosine Receptor Kinase ◽  
Public Drug

CADTH recommends that Vitrakvi be reimbursed by public drug plans for treating adult and pediatric patients with locally advanced or metastatic solid tumours who have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, or where surgical resection is likely to result in severe morbidity and have no satisfactory treatment options, but only if certain conditions are met. Vitrakvi should only be covered to treat patients with advanced solid tumours who have an NTRK gene fusion, who have previously failed on all standard treatments for their current tumour site, and who will be able to tolerate the treatment. Vitrakvi should only be reimbursed as single-agent therapy if it is prescribed by a clinician with expertise in the use of antineoplastic drugs and if the cost of Vitrakvi is reduced.

scholarly journals Pembrolizumab (Keytruda)

2021 ◽  
Vol 1 (12) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Cost Effectiveness ◽  
Pediatric Patients ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Salvage Chemotherapy ◽  
Clinician Perspectives ◽  
Multi Agent

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses pembrolizumab (Keytruda) 200 mg in adults or 2 mg/kg in pediatrics administered intravenously every 3 weeks. Indication: Treatment of adult and pediatric patients with refractory or relapsed cHL, as monotherapy, who have failed ASCT, or who are not candidates for multi-agent salvage chemotherapy and ASCT.

scholarly journals Risdiplam (Evrysdi)

2021 ◽  
Vol 1 (11) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Cost Effectiveness ◽  
Spinal Muscular Atrophy ◽  
Drug Class ◽  
Muscular Atrophy ◽  
Clinical Effectiveness ◽  
Oral Solution ◽  
Clinician Perspectives

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses risdiplam (Evrysdi), powder for oral solution. Indication: Pre-NOC: for the treatment of spinal muscular atrophy; Final: for the treatment of spinal muscular atrophy in patients 2 months and older.

scholarly journals Onasemnogene Abeparvovec (Zolgensma)

2021 ◽  
Vol 1 (9) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Single Dose ◽  
Cost Effectiveness ◽  
Pediatric Patients ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Survival Motor Neuron ◽  
Smn1 Gene ◽  
Smn2 Gene ◽  
Clinician Perspectives ◽  
Biallelic Mutations

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses onasemnogene abeparvovec (Zolgensma), given as a single-dose IV infusion of 1.1 × 1014 vector genomes/kg Indication: For the treatment of pediatric patients with 5q SMA with biallelic mutations in the survival motor neuron 1 (SMN1) gene and: 3 or fewer copies of the SMN2 gene or infantile-onset SMA  

scholarly journals Nivolumab (Opdivo) in combination with Ipilimumab (Yervoy)

2021 ◽  
Vol 1 (9) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Cost Effectiveness ◽  
Systemic Therapy ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Adult Patients ◽  
Clinician Perspectives ◽  
Prior Systemic Therapy

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses nivolumab (Opdivo) 10 mg/mL for injection; administered by IV infusion and ipilimumab (Yervoy) 5 mg/mL for injection; administered by IV infusion Indication: Nivolumab (Opdivo) in combination with ipilimumab (Yervoy) is indicated for the treatment of adult patients with unresectable MPM who have not received prior systemic therapy for MPM

scholarly journals Luspatercept (Reblozyl)

2021 ◽  
Vol 1 (8) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Cost Effectiveness ◽  
Blood Cell ◽  
Red Blood Cell ◽  
Subcutaneous Injection ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Adult Patients ◽  
Red Blood Cell Transfusion ◽  
Beta Thalassemia ◽  
Clinician Perspectives

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses luspatercept (Reblozyl), 25 mg/vial, 75 mg/vial, powder for solution for subcutaneous injection. Indication: For the treatment of adult patients with red blood cell transfusion-dependent anemia associated with beta-thalassemia.

scholarly journals Risperidone for Extended-Release Injectable Suspension (Perseris)

2021 ◽  
Vol 1 (11) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Cost Effectiveness ◽  
Subcutaneous Injection ◽  
Extended Release ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Clinician Perspectives

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses risperidone for extended-release injectable suspension (Perseris), powder for suspension, 90 mg or 120 mg subcutaneous injection. Indication: Treatment of schizophrenia in adults.

Venetoclax (Venclexta)

2021 ◽  
Vol 1 (10) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Cost Effectiveness ◽  
Induction Chemotherapy ◽  
Low Dose ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Newly Diagnosed ◽  
Clinician Perspectives ◽  
Low Dose Cytarabine

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses venetoclax (Venclexta), 10 mg, 50 mg, and 100 mg oral tablets. Indication: In combination with azacitidine or low-dose cytarabine for the treatment of patients with newly diagnosed AML who are 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.

scholarly journals Azacitidine (Onureg)

2022 ◽  
Vol 2 (1) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Complete Remission ◽  
Myeloid Leukemia ◽  
Blood Count ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Hematopoietic Stem ◽  
Consolidation Treatment ◽  
Clinician Perspectives ◽  
Acute Myeloid ◽  
Count Recovery

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses azacitidine (Onureg), tablet 300 mg, oral. Indication: Maintenance therapy in adult patients with acute myeloid leukemia who achieved complete remission or complete remission with incomplete blood count recovery following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation.

scholarly journals Pembrolizumab (Keytruda)

2021 ◽  
Vol 1 (9) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Colorectal Cancer ◽  
Cost Effectiveness ◽  
Microsatellite Instability ◽  
Mismatch Repair ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Line Treatment ◽  
First Line ◽  
Clinician Perspectives ◽  
First Line Treatment

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses pembrolizumab (Keytruda) 200 mg administered intravenously Indication: As monotherapy, for the first-line treatment of adults with metastatic microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) colorectal cancer

Sign in / Sign up

Export Citation Format

Share Document